News & SEC Filings

View the latest news and SEC filings

News

LONDON and RALEIGH, N.C., May 21, 2025 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will participate in fireside chats at the following conferences in June 2025: Jefferies Global Healthcare Conference Date: Wednesday, June

Analyses support Ohtuvayre® (ensifentrine) as a first-in-class selective dual inhibitor of PDE3 and PDE4 for a broad COPD population LONDON and RALEIGH, N.C., May 06, 2025 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona” or the “Company”), a biopharmaceutical company focused on

Total net revenue of $76.3 million from Q1 2025 driven by Ohtuvayre ® net sales of $71.3 million (+95% vs Q4 2024) ~25,000 prescriptions filled in Q1 2025 Q1 2025 revenue exceeds operating expenses excluding non-cash charges Conference call today at 9:00 a.m. EDT / 2:00 p.m.

LONDON and RALEIGH, N.C., April 15, 2025 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the first quarter ended March 31, 2025 on Tuesday, April 29, 2025 and host an investment community conference call

SEC Filings

Date Form Filing Group

September 25, 2018

Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act

6-K

Current Reports

August 14, 2018

Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act

6-K

Current Reports

August 7, 2018

Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act

6-K

Current Reports

June 28, 2018

Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act

6-K

Current Reports

June 4, 2018

Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act

6-K

Current Reports

June 1, 2018

EFFECT

EFFECT

Other

May 30, 2018

CORRESP

CORRESP

Other

May 29, 2018

UPLOAD

UPLOAD

Other

PDF

May 22, 2018

Registration statement for certain foreign private issuers offered for certain transactions

F-3

Registration Statements

Developing novel therapeutics for respiratory diseases

Verona Pharma (Nasdaq:VRNA) is focused on delivering our strategy and creating value for shareholders.